Mark For: STEBFYBA® trademark registration is intended to cover the categories of
Research | OneLook Acronym Finder |
Serial Number | 88226528 |
Registration Number | 5987587 |
Mark Literal Elements | STEBFYBA |
Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
Mark Type | TRADEMARK |
Register | PRINCIPAL |
Current Location | PUBLICATION AND ISSUE SECTION 2020-02-18 |
Basis | 44(e) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | No |
Filed ITU | Yes |
44D Filed | Yes |
44E Current | Yes |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Anthony P. Venturino |
Attorney Docket Number | 72924-000846 |
2018-12-12 | Application Filed |
2019-01-04 | Location: NEW APPLICATION PROCESSING |
2019-01-04 | Status: Live/Pending |
2019-01-04 | Transaction Date |
2019-05-21 | Published |
2019-05-21 | Published for Opposition |
2020-02-18 | Location: PUBLICATION AND ISSUE SECTION |
2020-02-18 | Status: Registered. The registration date is used to determine when post-registration maintenance documents are due. |
2020-02-18 | Trademark Registered |
Party: | CHIESI FARMACEUTICI S.P.A. |
Address | VIA PALERMO 26/A PARMA ITALY 43122 |
Legal Entity Type | Joint Stock Company |
Legal Entity State | ITALY |
Drawing | JPEG | 2018-12-12 |
TEAS RF New Application | MULTI | 2018-12-12 |
XSearch Search Summary | APPLICATION/XML | 2019-03-12 |
Amendment to Delete or Correct Basis | MULTI | 2019-03-13 |
Examiners Amendment | XML | 2019-03-14 |
Amendment and Mail Process Complete | MULTI | 2019-03-15 |
TRAM Snapshot of App at Pub for Oppostn | MULTI | 2019-03-22 |
Notice of Publication | XML | 2019-05-01 |
Notification Of Notice of Publication | XML | 2019-05-01 |
OG Publication Confirmation | APPLICATION/XML | 2019-05-21 |
Notice of Allowance | APPLICATION/XML | 2019-07-16 |
Post Publication Amendment | MULTI | 2019-12-10 |
Amendment to Delete or Correct Basis | MULTI | 2020-01-15 |
ITU Unit Action | MULTI | 2020-01-15 |
Prosecution History for Canceling NOA | MULTI | 2020-01-15 |
Registration Certificate | 2020-02-18 |
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations and substances for the treatment of pain, cardiovascular disorders, alimentary tract and metabolism problems, respiratory diseases, endocrine, musculoskeletal, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmological, otologicals, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue; anti-inflammatory and anti-rheumatics drugs; pharmaceutical preparations, namely, immunomodulators; pharmaceutical preparations, namely, hematological agents being pharmaceuticals for the treatment of hematological diseases; Enzyme replacement therapy preparations; Enzyme replacement therapy products, namely, infusions, liquids, tablets and powders for human use in the treatment of genetic disorders for medical purposes; Therapeutic cellular and stem cell compositions for medical use
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations and substances for the treatment of pain, cardiovascular disorders, alimentary tract and metabolism problems, respiratory diseases, endocrine, musculoskeletal, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmological, otologicals, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue; anti-inflammatory and anti-rheumatics drugs; pharmaceutical preparations, namely, immunomodulators; hematological agents being pharmaceuticals for the treatment of hematological diseases. Enzyme replacement therapy preparations; Enzyme replacement therapy products, namely, infusions, liquids, tablets and powders for human use in the treatment of genetic disorders. Therapeutic cellular and stem cell compositions for clinical or medical use |
GS0051 | Pharmaceutical preparations and substances for the treatment of pain, cardiovascular disorders, alimentary tract and metabolism problems, respiratory diseases, endocrine, musculoskeletal, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmological, otologicals, neurological, gastrointestinal, hormonal, dermatological and psychiatric related diseases and disorders and for the treatment of damaged skin and tissue; anti-inflammatory and anti-rheumatics drugs; pharmaceutical preparations, namely, immunomodulators; pharmaceutical preparations, namely, hematological agents being pharmaceuticals for the treatment of hematological diseases; Enzyme replacement therapy preparations; Enzyme replacement therapy products, namely, infusions, liquids, tablets and powders for human use in the treatment of genetic disorders for medical purposes; Therapeutic cellular and stem cell compositions for medical use |
Description | Date | Proceeding Number |
---|---|---|
REGISTERED-PRINCIPAL REGISTER | 2020-02-18 | |
1(B) BASIS DELETED; PROCEED TO REGISTRATION | 2020-01-14 | 71906 |
CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2020-01-13 | 71906 |
TEAS POST PUBLICATION AMENDMENT RECEIVED | 2019-12-10 | |
NOTICE OF ALLOWANCE CANCELLED | 2019-12-10 | 71906 |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-07-16 | |
PUBLISHED FOR OPPOSITION | 2019-05-21 | |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-05-21 | |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-05-01 | |
ASSIGNED TO LIE | 2019-04-12 | 70633 |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-03-21 | |
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2019-03-14 | 6328 |
EXAMINERS AMENDMENT E-MAILED | 2019-03-14 | 6328 |
EXAMINERS AMENDMENT -WRITTEN | 2019-03-14 | 92563 |
EXAMINER'S AMENDMENT ENTERED | 2019-03-14 | 88888 |
ASSIGNED TO EXAMINER | 2019-03-11 | 92563 |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2019-01-04 | |
NEW APPLICATION ENTERED IN TRAM | 2018-12-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.